Clinical trial
Phase II GM-CSF Plus Mitoxantrone in Hormone Refractory Prostate Cancer
NCT00477087
Study timeline
Study start (unknown)2006-07-01Date precision: month
Registry last updated2017-11-29
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Prostatic Neoplasmsunresolved
Interventions
MitoxantroneDRUG · verified · RxNorm: mitoxantrone
GM-CSFDRUG
Sponsors & collaborators
Stanford Universitylead sponsor
Bayercollaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT00477087 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.